Does intravitreal injection of bevacizumab have an effect on the blood-aqueus barrier function?

Ziemssen, Focke; Warga, M.; Neuhann, Irmingard M.; Leitritz, Martin Alexander; Biester, Sabine; Grisanti, Salvatore; Bartz-Schmidt, Karl-Ulrich

doi:10.1136/bjo.2006.092262

Cited by 23 publications

(6 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These were easily managed with topical corticosteroids. However, this is consistent with the findings of Ziemssen and colleagues that showed that the aqueous flare in 60 patients injected with 1.25 mg of intravitreal bevacizumab for age-related macular degeneration had a slight increase only in the first post-injection day as measured by the flaremeter [33].…”

Section: Discussionsupporting

confidence: 90%

Twelve-month safety of intravitreal injections of bevacizumab (Avastin®): results of the Pan-American Collaborative Retina Study Group (PACORES)

Martínez-Castellanos

Quiroz‐Mercado

et al. 2007

Graefes Arch Clin Exp Ophthalmol

423

254

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 90%

Twelve-month safety of intravitreal injections of bevacizumab (Avastin®): results of the Pan-American Collaborative Retina Study Group (PACORES)

Martínez-Castellanos

Quiroz‐Mercado

et al. 2007

Graefes Arch Clin Exp Ophthalmol

423

254

View full text Add to dashboard Cite

show abstract

“…Rarely, intraocular inflammation was observed 37 . A small series of patients did not reveal an increase in flare 38,39 . In electrophysiological studies no negative side-effects were seen on the retina.…”

Section: Clinical Applicationmentioning

confidence: 81%

Bevacizumab: Off-label use in ophthalmology

Grisanti¹,

Ziemssen²

2007

Indian J Ophthalmol

View full text Add to dashboard Cite

Bevacizumab is a full-length, humanized monoclonal antibody directed against all the biologically active isoforms of vascular endothelial growth factor (VEGF-A). The antibody was initially designed and studied as an anti-angiogenic strategy to treat a variety of solid tumors. After approval by the US Food and Drug Administration, bevacizumab gained access into ophthalmology to treat various types of neovascular diseases. Since the first report in 2005 more than 100 publications share the experience with bevacizumab in ophthalmology. Two authors independently assessed the research results from Pubmed to April 2007. The reference list is a selection of key publications related to the issue. Currently, there is no well-designed randomized controlled trial yet to establish the efficacy and safety of intraocular bevacizumab for any ocular disease in spite of its assumed characteristics representing the most cost-effective VEGF inhibitor.

show abstract

“…6 Another article showed a negligible change in flare at 1 day, nonsignificant decrease at 1 week, and significant decrease after 1 month. 7 These articles did not state whether the eyes were anti-VEGF-naive. If they were, then the change in flare could be because of decreasing leakage from initial treatment of the choroidal neovascularization.…”

Section: Discussionmentioning

confidence: 97%

Changes in Flare After Intravitreal Injection of Three Different Anti-Vascular Endothelial Growth Factor Medications

Blaha

Brooks

Mackel

et al. 2015

Retina

View full text Add to dashboard Cite

show abstract

Does intravitreal injection of bevacizumab have an effect on the blood-aqueus barrier function?

Cited by 23 publications

References 5 publications

Twelve-month safety of intravitreal injections of bevacizumab (Avastin®): results of the Pan-American Collaborative Retina Study Group (PACORES)

Twelve-month safety of intravitreal injections of bevacizumab (Avastin®): results of the Pan-American Collaborative Retina Study Group (PACORES)

Bevacizumab: Off-label use in ophthalmology

Changes in Flare After Intravitreal Injection of Three Different Anti-Vascular Endothelial Growth Factor Medications

Contact Info

Product

Resources

About